BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Inside Plan with Houseplants: An Aide- Figure out How to Take part in Open Conversations Around 5G Pinnacles
- Iranian naval commander Alireza Tangsiri killed in attack, says Israel
- Vote in favor of your Favored sort of footwear
- FACT FOCUS: Trump sows confusion on number of childhood vaccinations
- The Best Games On the planet
- Figure out How to Ascertain the Restitution Time frame for Your Sunlight based chargers
- Major railway disruptions persist as Germany braces for more snow
- Figure out How to Explore Land Close to 5G Pinnacles
